abn401
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 30, 2019 (NCT04052971)
Timeline
Indications
Studied for
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05882292 | Phase 2 | Jul 1, 2023 | Yonsei University |
| NCT05541822 | Phase 2 | Dec 31, 2022 | Abion Inc |
| NCT05248074 | Phase 1 | Jan 4, 2022 | Abion Inc |
| NCT04052971 | Phase 1/Phase 2 (Phase 2) | Aug 30, 2019 | Abion Inc, Linear Clinical Research, Novotech |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abion Inc | For profit | 3 | 3 | 2 | 2019 |
| Linear Clinical Research | For profit | 1 | 0 | 1 | 2019 |
| Novotech | For profit | 1 | 0 | 1 | 2019 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1